China’s Fosun Pharma Targets $650 Million IPO With Prudential Insurance As Cornerstone Investor
This article was originally published in PharmAsia News
Executive Summary
China’s largest non-state-owned pharma company Fosun Pharma commenced an initial global offering in Hong Kong, and nearly half of the money raised will be used for M&A. But the $650 million expected to be raised is much smaller than the rumored $800 million.
You may also be interested in...
With Pfizer As Cornerstone Investor, Will Shanghai Pharmaceutical Be Largest Pharma IPO Ever?
SHANGHAI - Shanghai Pharmaceutical Holdings Co. Ltd is set for what could be the largest IPO by a pharmaceutical company ever, surpassing Ostuka Holding's $2.4 billion IPO from last year
China Distributor Consolidation Heats Up: Sinopharm Looks To Raise $440 Million Ahead Of Shanghai Pharma IPO
SHANGHAI - China's largest drug distributor Sinopharm Group Co. Ltd. April 25 placed a secondary offering of roughly 138 million H shares in Hong Kong looking to raise HK$3.4 billion ($440 million) to fund more acquisitions. The move comes just ahead of the initial public offering in Hong Kong of Sinopharm's biggest competitor Shanghai Pharmaceutical Holdings Co. Ltd, and will add more heat to the consolidation war in China's distribution sector
Shanghai Fosun Omni Pharma Execs On The Market For Inhalation Products In China: An Interview With PharmAsia News (Part 2 of 2)
Shanghai Fosun Omni Pharmaceutical was founded in 2006 as a joint venture between two former principal R&D leaders from Ivax/Teva and Shanghai Fosun Pharmaceutical, a leading pharmaceutical enterprise in China. Shanghai-based Omni's CEO Kai Zhang and Chief Operating Officer Shaochuan Zeng, the former leaders from Ivax/Teva, spoke with PharmAsia News' Shanghai bureau about their operation and the market for inhalation products in China.